immune checkpoint inhibitors

Data haul improves immunotherapy response prediction

Vanderbilt biostatisticians have developed an immunotherapy response model that outperforms existing predictive models.

T cells (orange) engage with cancer cells (blue). Halle Borowski, an artist and senior at the College of William and Mary, worked with Drs. Mary Philip and Jess Roetman to create this oil painting, inspired by their research, as part of the Vanderbilt Institute for Infection, Immunology, and Inflammation (VI4) Artist-in-Residence program (

Tumor antigens key to improving cancer immunotherapy: study

Vanderbilt researchers are working to better design immune therapies that attack tumors without also attacking healthy normal tissue in patients.

Cardiac antigen identified as mechanism for heart complication with immunotherapy-related myocarditis

Researchers from from Vanderbilt-Ingram Cancer Center have identified the mechanism for the deadly heart inflammation myocarditis.

Vanderbilt biostatisticians launch Cancer-Immu data portal for predicting response to immune checkpoint blockade immunotherapy

A new data portal called Cancer-Immu established by a team of Vanderbilt University Medical Center biostatisticians can help cancer clinicians and researchers predict which patients will respond to immune checkpoint inhibitors.